Ethos Financial Group LLC Buys New Stake in Axon Enterprise, Inc $AXON

by · The Cerbat Gem

Ethos Financial Group LLC bought a new stake in Axon Enterprise, Inc (NASDAQ:AXON – Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 259 shares of the biotechnology company’s stock, valued at approximately $214,000.

Several other institutional investors and hedge funds have also bought and sold shares of the company. TCTC Holdings LLC lifted its holdings in shares of Axon Enterprise by 75.0% during the 1st quarter. TCTC Holdings LLC now owns 56 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 24 shares during the last quarter. Banque Transatlantique SA acquired a new position in Axon Enterprise during the 1st quarter valued at about $31,000. Flaharty Asset Management LLC purchased a new stake in Axon Enterprise in the first quarter valued at about $33,000. Hemington Wealth Management boosted its holdings in Axon Enterprise by 70.8% in the second quarter. Hemington Wealth Management now owns 41 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 17 shares in the last quarter. Finally, Whipplewood Advisors LLC boosted its holdings in Axon Enterprise by 192.9% in the second quarter. Whipplewood Advisors LLC now owns 41 shares of the biotechnology company’s stock worth $34,000 after acquiring an additional 27 shares in the last quarter. 79.08% of the stock is owned by hedge funds and other institutional investors.

Axon Enterprise Stock Up 2.6%

Shares of AXON stock opened at $602.51 on Friday. Axon Enterprise, Inc has a twelve month low of $469.24 and a twelve month high of $885.91. The stock has a market cap of $47.30 billion, a P/E ratio of 148.77, a P/E/G ratio of 29.49 and a beta of 1.45. The stock has a 50 day moving average of $719.61 and a 200 day moving average of $734.79. The company has a current ratio of 2.95, a quick ratio of 2.71 and a debt-to-equity ratio of 0.63.

Axon Enterprise (NASDAQ:AXON – Get Free Report) last released its quarterly earnings data on Tuesday, November 4th. The biotechnology company reported $1.17 EPS for the quarter, missing the consensus estimate of $1.63 by ($0.46). The company had revenue of $710.64 million during the quarter, compared to analysts’ expectations of $704.83 million. Axon Enterprise had a return on equity of 6.80% and a net margin of 13.64%.The company’s revenue for the quarter was up 30.6% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.45 EPS. Axon Enterprise has set its Q4 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, sell-side analysts expect that Axon Enterprise, Inc will post 5.8 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have recently issued reports on AXON shares. Northland Securities set a $800.00 price objective on shares of Axon Enterprise in a report on Tuesday, August 5th. Morgan Stanley set a $885.00 price target on shares of Axon Enterprise and gave the company an “overweight” rating in a research note on Friday, July 11th. Barclays decreased their price target on shares of Axon Enterprise from $861.00 to $702.00 and set an “overweight” rating for the company in a report on Thursday. Craig Hallum raised shares of Axon Enterprise from a “hold” rating to a “buy” rating and set a $900.00 price objective on the stock in a report on Tuesday, August 5th. Finally, Zacks Research downgraded Axon Enterprise from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 2nd. Fifteen analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $810.71.

Get Our Latest Stock Report on Axon Enterprise

Insider Activity

In related news, CAO Jennifer H. Mak sold 77 shares of the firm’s stock in a transaction on Monday, September 15th. The shares were sold at an average price of $760.00, for a total transaction of $58,520.00. Following the sale, the chief accounting officer owned 15,003 shares in the company, valued at approximately $11,402,280. This trade represents a 0.51% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Jeri Williams sold 100 shares of Axon Enterprise stock in a transaction on Thursday, September 11th. The shares were sold at an average price of $752.54, for a total transaction of $75,254.00. Following the completion of the transaction, the director directly owned 1,416 shares of the company’s stock, valued at $1,065,596.64. The trade was a 6.60% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 59,932 shares of company stock valued at $45,115,616 in the last three months. Corporate insiders own 4.40% of the company’s stock.

Axon Enterprise Company Profile

(Free Report)

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.

See Also

Want to see what other hedge funds are holding AXON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axon Enterprise, Inc (NASDAQ:AXON – Free Report).